Cannabidiol for epilepsies, myoclonic

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 10 registered trials.

Why this status

  1. 19 Mar 2014: Trial registered, NCT02091375
  2. 25 Aug 2014: Trial registered, NCT02224573
  3. 25 Aug 2014: Trial registered, NCT02224703
  4. 17 Dec 2014: Trial registered, NCT02318602
  5. 30 Mar 2015: Trial started, NCT02091375
  6. 13 Apr 2015: Trial started, NCT02224703
  7. 11 Jun 2015: Trial started, NCT02224573
  8. 8 Jan 2016: Trial started, NCT02318602
  9. 7 Jul 2021: Trial started, NCT05044819
  10. 16 Sep 2021: Trial registered, NCT05044819

The trials

NCT02091206: A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)

State
Completed
Phase
Phase 2
People
34 taking part
Started
22 Oct 2014
Primary completion
9 Mar 2015
Arms
GWP42003-P 5 mg/kg/day Dose, GWP42003-P 10 mg/kg/day Dose, GWP42003-P 20 mg/kg/day Dose
Results
Posted on the registry
  1. 19 Mar 2014: Trial registered
  2. 22 Oct 2014: Trial started
  3. 9 Mar 2015: Trial completed
  4. 19 Jul 2018: Trial results posted

NCT02091375: Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)

State
Completed
Phase
Phase 3
People
120 taking part
Started
30 Mar 2015
Primary completion
26 Nov 2015
Arms
GWP42003-P 20 mg/kg/day Dose
Results
Posted on the registry
Papers
doi:10.1056/nejmoa1611618, doi:10.1111/epi.16974
  1. 19 Mar 2014: Trial registered
  2. 30 Mar 2015: Trial started
  3. 26 Nov 2015: Trial completed
  4. 20 Jul 2018: Trial results posted

NCT02224573: An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes

State
Completed
Phase
Phase 3
People
681 taking part
Started
11 Jun 2015
Primary completion
24 Sep 2020
Arms
GWP42003-P
Results
Posted on the registry
Papers
doi:10.1111/epi.17000, doi:10.1111/epi.17036
  1. 25 Aug 2014: Trial registered
  2. 11 Jun 2015: Trial started
  3. 24 Sep 2020: Trial completed
  4. 3 Feb 2022: Trial results posted

NCT02224703: GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome

State
Completed
Phase
Phase 3
People
199 taking part
Started
13 Apr 2015
Primary completion
9 Apr 2018
Arms
10 mg/kg/day GWP42003-P, 20 mg/kg/day GWP42003-P
Results
Posted on the registry
Papers
doi:10.1001/jamaneurol.2020.0073, doi:10.1111/epi.16974
  1. 25 Aug 2014: Trial registered
  2. 13 Apr 2015: Trial started
  3. 9 Apr 2018: Trial completed
  4. 1 Aug 2019: Trial results posted

NCT02318563: Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome

State
Withdrawn before it started
Phase
Phase 3
People
0 taking part
Started
30 Dec 2017
Primary completion
17 Jun 2018
Arms
Cannabidiol Oral Solution
Results
None posted
  1. 17 Dec 2014: Trial registered
  2. 4 Jan 2018: Trial withdrawn

NCT02318602: Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder

State
Completed
Phase
Phase 3
People
52 taking part
Started
8 Jan 2016
Primary completion
22 Jun 2017
Arms
Infants, Children, Adolescents
Results
Posted on the registry
  1. 17 Dec 2014: Trial registered
  2. 8 Jan 2016: Trial started
  3. 22 Jun 2017: Trial completed
  4. 26 Jul 2018: Trial results posted

NCT04485104: Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures

State
Stopped early
Phase
Phase 3
People
3 taking part
Started
19 May 2021
Primary completion
28 Jan 2025
Arms
GWP42003-P
Results
Posted on the registry
  1. 24 Jul 2020: Trial registered
  2. 19 May 2021: Trial started
  3. 28 Jan 2025: Trial terminated
  4. 31 Oct 2025: Trial results posted

NCT05044819: Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

State
Under way
Phase
Phase 4
People
154 taking part
Started
7 Jul 2021
Primary completion
1 Aug 2027
Arms
Cannabidiol
Results
None posted
  1. 7 Jul 2021: Trial started
  2. 16 Sep 2021: Trial registered

NCT05288283: Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures

State
Stopped early
Phase
Phase 3
People
3 taking part
Started
31 Oct 2022
Primary completion
28 Sep 2023
Arms
GWP42003-P
Results
Posted on the registry
  1. 21 Mar 2022: Trial registered
  2. 31 Oct 2022: Trial started
  3. 28 Sep 2023: Trial terminated
  4. 3 Feb 2025: Trial results posted

NCT06924827: A Study to Investigate the Transition of Children From 'Artisanal" Cannabidiol (CBD) to Epidiolex

State
Not started
Phase
Phase 4
People
25 planned
Started
1 Jan 2027
Primary completion
1 Jan 2028
Arms
Epidiolex Treatment
Results
None posted
  1. 11 Apr 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Cardiolrx, Canapure PH, Cannabidiol (Epidiolex), Cannabidiol Oral Solution, Epidiolex, Epidiolex 100 mg/mL Oral Solution, Epidyolex, GWP42003-P 10 mg/kg/day Dose, GWP42003-P 20 mg/kg/day Dose, GWP42003-P 5 mg/kg/day Dose, MediCabilis.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.